Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, M. K. | - |
dc.contributor.author | Rhee, E. -J. | - |
dc.contributor.author | Han, K. A. | - |
dc.contributor.author | Woo, A. C. | - |
dc.contributor.author | Lee, M. -K. | - |
dc.contributor.author | Ku, B. J. | - |
dc.contributor.author | Chung, C. H. | - |
dc.contributor.author | Kim, K. -A. | - |
dc.contributor.author | Lee, H. W. | - |
dc.contributor.author | Park, I. B. | - |
dc.contributor.author | Park, J. Y. | - |
dc.contributor.author | Jang, H. C. Chul | - |
dc.contributor.author | Park, K. S. | - |
dc.contributor.author | Jang, W. I. | - |
dc.contributor.author | Cha, B. Y. | - |
dc.date.available | 2020-02-28T10:41:20Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-03 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10735 | - |
dc.description.abstract | The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin (HbA1c) 7.0-10.0%, on stable metformin >= 1000 mg/day] were randomized 2 : 1 to receive 20 mg teneligliptin plus metformin (n=136) or placebo plus metformin (n=68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were -0.78 % and -1.24 mmol/l (22.42 mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in Korean patients with type 2 diabetes. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.subject | COMBINATION THERAPY | - |
dc.subject | JAPANESE PATIENTS | - |
dc.subject | GLUCOSE CONTROL | - |
dc.subject | METAANALYSIS | - |
dc.title | Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000349399200012 | - |
dc.identifier.doi | 10.1111/dom.12424 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, v.17, no.3, pp.309 - 312 | - |
dc.identifier.scopusid | 2-s2.0-84922025125 | - |
dc.citation.endPage | 312 | - |
dc.citation.startPage | 309 | - |
dc.citation.title | DIABETES OBESITY & METABOLISM | - |
dc.citation.volume | 17 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Park, I. B. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | DPP-4 inhibitors | - |
dc.subject.keywordAuthor | Korean | - |
dc.subject.keywordAuthor | metformin | - |
dc.subject.keywordAuthor | teneligliptin | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | GLUCOSE CONTROL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.